Clinical Trial

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

Completed
View on ClinicalTrials.gov →
Summary
The aim of this study was to evaluate patient profiles, treatment patterns, and outcomes of hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer (mBC) patients treated with a 1L cyclin dependent kinase 4/6 inhibitor (CDK4/6i) in the real-world setting.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-30.
Trial Details
NCT Number NCT07512063
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer
Enrollment 480 participants
Start Date 2024-10-08
Primary Completion 2025-03-17 (estimated)
Study Completion 2025-03-17 (estimated)
Updated on ClinicalTrials.gov 2026-04-13